
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical is a company with a positive outlook for several reasons. Firstly, the company has a dominant market position in phakic IOLs, which are used in refractive surgery and make up almost all of Staar Surgical's revenue. Secondly, the company has shown strong growth potential in China, with a 111% increase in net sales and a 21.4% margin in the second quarter of 2026. This growth is expected to continue with the appointment of a permanent CEO and the resolution of distributor disruptions. Lastly, the company has a solid financial position, with a debt-free balance sheet and a positive outlook for profitability in the future.
Bears say
Staar Surgical is facing potential market share loss in the near term due to competitors entering the market with toric lenses, creating a technology gap. However, the company has built a strong brand equity among patients in China, which may offset some of the competition. With the potential for market share ramp by competitors after patient outcome assessments, it is important for analysts to monitor the company's performance closely. As of fiscal year 2020, the company had a strong financial position with a cash and cash equivalents balance of $147.7 million and a net income of $22 million.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares